Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other financing activities (2017 - 2021)

Aclaris Therapeutics (ACRS) has 5 years of Other financing activities data on record, last reported at $300000.0 in Q2 2021.

  • For Q2 2021, Other financing activities rose 164.79% year-over-year to $300000.0; the TTM value through Jun 2021 reached -$289000.0, up 30.53%, while the annual FY2024 figure was -$377000.0, 4612.5% down from the prior year.
  • Other financing activities reached $300000.0 in Q2 2021 per ACRS's latest filing, up from -$31000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $378000.0 in Q1 2018 and bottomed at -$753000.0 in Q4 2017.
  • Average Other financing activities over 5 years is -$89500.0, with a median of -$53500.0 recorded in 2018.
  • Peak YoY movement for Other financing activities: soared 251.32% in 2019, then plummeted 2472.22% in 2020.
  • A 5-year view of Other financing activities shows it stood at -$753000.0 in 2017, then soared by 89.91% to -$76000.0 in 2018, then skyrocketed by 251.32% to $115000.0 in 2019, then plummeted by 126.96% to -$31000.0 in 2020, then skyrocketed by 1067.74% to $300000.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $300000.0 in Q2 2021, -$31000.0 in Q4 2020, and -$95000.0 in Q3 2020.